a continuous tube formed by a row of elongated cells lacking intervening end walls
an enclosed conduit for a fluid
a bodily passage or tube lined with epithelial cells and conveying a secretion or other substance; "the tear duct was obstructed"; "the alimentary canal"; "poison is released through a channel in the snakes fangs" (同)epithelial duct, canal, channel
any malignant tumor derived from epithelial tissue; one of the four major types of cancer
Italian composer of operas (1801-1835) (同)Vincenzo Bellini
Collecting duct carcinoma (CDC) (also known as Bellini duct carcinoma[1]), is a type of kidney cancer that originates in the papillary duct of the kidney. It is rare, accounting for 1-3% of all kidney cancers.[2] It is also recently described; a 2002 review found just 40 case reports worldwide.[3] Previously, due to its location, CDC was commonly diagnosed as renal cell carcinoma or a subtype of renal cell carcinoma.[4] However, CDC does not respond well to chemotherapy drugs used for renal cell carcinoma, and progresses and spreads more quickly.
Contents
1Signs and symptoms
2Histology
3Treatment
4History
5References
6External links
Signs and symptoms
Signs and symptoms are as for kidney cancer.
Histology
Histologic examination of collecting duct carcinoma demonstrates an infiltrative lesion with tubulopapillary, irregular channels lined by high grade hobnail cells with marked desmoplastic response and brisk neutrophilic infiltrate.
Treatment
This section is empty. You can help by adding to it. (February 2018)
History
CDC was thought to be renal cell carcinoma, until "recently developed techniques of lectin histochemistry" helped forward knowledge of kidney duct cancers.[5]
References
^Amin MB, MacLennan GT, Gupta R, Grignon D, Paraf F, Vieillefond A, Paner GP, Stovsky M, Young AN, Srigley JR, Cheville JC (March 2009). "Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma". Am. J. Surg. Pathol. 33 (3): 384–92. doi:10.1097/PAS.0b013e3181872d3f. PMID 19011562.
^Fakhrai N, Haitel A, Balassy C, Zielinski CC, Schmidinger M (January 2005). "Major response and clinical benefit following third-line treatment for Bellini duct carcinoma". Wien. Klin. Wochenschr. 117 (1–2): 63–5. doi:10.1007/s00508-004-0289-4. PMID 15986594.
^Singh I, Nabi G (2002). "Bellini duct carcinoma: review of diagnosis and management" (PDF). Int Urol Nephrol. 34 (1): 91–5. doi:10.1023/A:1021315130481. PMID 12549647.
^Méjean A, Rouprêt M, Larousserie F, Hopirtean V, Thiounn N, Dufour B (April 2003). "Is there a place for radical nephrectomy in the presence of metastatic collecting duct (Bellini) carcinoma?". J. Urol. 169 (4): 1287–90. doi:10.1097/01.ju.0000050221.51509.f5. PMID 12629344.
^O Natsume; S Ozono; T Futami & M Ohta (1997). "Bellini duct carcinoma: a case report". Japanese Journal of Clinical Oncology. 27 (2): 107–110. doi:10.1093/jjco/27.2.107. PMID 9152800. Retrieved 2008-06-03.
External links
Classification
D
ICD-10: C64
MeSH: D002292
External resources
Orphanet: 247203
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
1. 非淡明細胞型腎癌に対する治療アプローチ the treatment approach to non clear cell renal carcinoma
2. 腎細胞癌の疫学、病理、および病因 epidemiology pathology and pathogenesis of renal cell carcinoma
3. 腎細胞癌患者における予後因子 prognostic factors in patients with renal cell carcinoma
4. 腎細胞癌の臨床症状、評価、および病期分類 clinical manifestations evaluation and staging of renal cell carcinoma
English Journal
Targeting FAK scaffold functions inhibits human renal cell carcinoma growth.
International journal of cancer. Journal international du cancer.Int J Cancer.2015 Oct 1;137(7):1549-59. doi: 10.1002/ijc.29522. Epub 2015 Apr 9.
Human conventional renal cell carcinoma (CCC) remains resistant to current therapies. Focal Adhesion Kinase (FAK) is upregulated in many epithelial tumors and clearly implicated in nearly all facets of cancer. However, only few reports have assessed whether FAK may be associated with renal tumorigen
Very late recurrence of renal cell carcinoma experiencing long-term response to sunitinib: a case report.
Messina C1, Di Meglio A, Nuzzo PV, Boccardo F, Ricci F.
Tumori.Tumori.2015 Post author correction;0(0):0. doi: 10.5301/tj.5000268. Epub 2015 May 30.
Renal cell carcinoma (RCC) is responsible for 4% of all neoplasms in adults and for 80% of all primary renal tumors. Metastatic RCC is resistant to all cytotoxic agents and generally prognosis is poor. However, the clinical behavior of RCC is unpredictable, and late recurrences of disease can occur
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Nouhaud FX1, Pfister C, Defortescu G, Giwerc A, Charbit D, Gouerant S, Sabourin JC, Di Fiore F.
To assess the impact of baseline chronic kidney disease on targeted therapy (TT)-induced toxicities and survival in patients treated for metastatic renal cell carcinoma (mRCC). Data from patients receiving first-line TT from January 2006 to June 2012 were collected retrospectively. TT side effects,
… The right renal tumor was not a typical renal cell carcinoma, so we considered the presence of belliniductcarcinoma and renal pelvis carcinoma, we performed right nephroureterectomy. … Histopathological diagnosis was urothelial carcinoma with glandular differentiation of the renal pelvis. …
Bellini duct carcinoma is also known by the names tubulocystic or low grade collecting duct carcinoma. It is a rare kind of cancer (it is somewhat like kidney cancer) that originates in the kidney, that is in the duct of Bellini of kidney.
Featured Image Picture of Psoriasis A reddish, scaly rash often located over the surfaces of the elbows, knees, scalp, and around or in the ears, navel, genitals ... Bellini duct carcinoma: (BDC) A rare type of kidney cancer that ...